Alpha Tau and Samsung Medical Center Sign MOU to Explore Clinical Trial of Alpha DaRT® for Pancreatic Cancer Patients in Korea
Alpha Tau Medical signed an MOU with Samsung Medical Center in Seoul to explore a potential Alpha DaRT clinical trial in pancreatic cancer patients — the therapy's first planned trial in South Korea. Any trial remains subject to regulatory and ethics committee approvals, and the MOU is exploratory with no financial terms disclosed.
Key figures
- Drug Name
- Alpha DaRT
- Korea five year survival rate
- 17.0%
- Smc pancreatectomies 2008 2025
- 4000
- Korea pancreatic diagnoses 2023
- 9748
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.